Sanofi Chief Executive Officer Olivier Brandicourt attended the China Development Forum and spoke at the Economic Summit

-Showing commitment to help promote the rapid implementation of rare diseases treatment in China

BEIJING, March 24, 2019 /PRNewswire/ — Sanofi Chief Executive Officer Olivier Brandicourt expressed yesterday that he is very glad to be able to participate in the 2019 edition of the China Development Forum, particularly as it marks the 20th anniversary of the Forum.

Sanofi Chief Executive Officer Olivier Brandicourt attended the China Development Forum and spoke at the Economic Summit
Sanofi Chief Executive Officer Olivier Brandicourt attended the China Development Forum and spoke at the Economic Summit

Hosted by the Development Research Centre of the State Council (DRC), the China Development Forum (CDF) is being held at the Diaoyutai State Guesthouse in Beijing from 23rd to 25th March, with the theme of “Greater Opening-up for Win-Win Cooperation.”

“Since the Healthy China blueprint was adopted two years ago, we realized how much policy has been adopted and the government has incredible ability to keep pace and continuously draft, adopt and then implement health policies. So it is clearly one of the key successes of China in reforming the healthcare system.” At the Economic Forum of CDF, Mr. Brandicourt spoke highly of Chinese authorities for having made significant strides to accelerate the listings of special care and rare disease medicines to address critical life-threatening conditions.

Sanofi stands by the millions of people battling long-term chronic conditions and the few sufferings from rare diseases. Mr. Brandicourt commented, “Considering our experience in developing groundbreaking rare diseases treatments and our strong experience in working with governments around the world, we, at Sanofi, are committed to working alongside the Chinese government to swiftly implement these policies and increase awareness among the public and healthcare actors.”

According to the organizers, 2019 marks the 70th anniversary of the establishment of People’s Republic of China. Its development over 70 years has strengthened China’s determination to adhere to the opening-up policy. China will continue to focus on its opening-up and innovative development, which are key concepts embedded in its new development plan.

More than 150 official representatives from foreign businesses attended the forum, including a total of 96 chairmen and CEOs of the world’s leading companies. The companies represented various industry sectors, including energy and minerals, financial insurance, aerospace, and information communications technology, equipment manufacturing, biopharmaceutical, and many more.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

About Sanofi China

In 1982, Sanofi opened its first office in China. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. Sanofi’s China headquarters in Shanghai are supported by 11 offices in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi. Sanofi has around 9,600 employees in China.

Sanofi has three manufacturing facilities in China to meet the increasing demand of the domestic market. These plants are located in Beijing, Hangzhou and Shenzhen.

Sanofi operates the China R&D Center and Asia Pacific R&D Hub in Shanghai, Global R&D Operations in Chengdu, and Global Research Institute in Suzhou. Sanofi’s R&D focuses on unmet medical needs, such as oncology, immunology, and metabolic diseases in China and the rest of the world.

For more information, please visit or subscribe to the Sanofi China official WeChat account: SanofiChina.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Photo –

Related Post